REGEN BIOPHARMA, INC. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7cd6766f-4270-4c86-93a6-3b855a475f08/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-338.5k | 2024-10-01 – 2025-09-30 | evidence 0001493152-25-029526 |
| FY 2024 | $-417.2k | 2023-10-01 – 2024-09-30 | evidence 0001641172-25-009968 |
| FY 2023 | $-687.0k | 2022-10-01 – 2023-09-30 | evidence 0001607062-23-000524 |
| FY 2022 | $-339.6k | 2021-10-01 – 2022-09-30 | evidence 0001607062-22-000694 |
| FY 2021 | $-200.8k | 2020-10-01 – 2021-09-30 | evidence 0001607062-21-000641 |
| FY 2020 | $-209.3k | 2019-10-01 – 2020-09-30 | evidence 0001607062-21-000250 |
| FY 2019 | $-756.8k | 2018-10-01 – 2019-09-30 | evidence 0001607062-21-000165 |
| FY 2018 | $-1.4M | 2017-10-01 – 2018-09-30 | evidence 0001607062-18-000491 |
| FY 2017 | $-2.5M | 2016-10-01 – 2017-09-30 | evidence 0001607062-18-000006 |
| FY 2016 | $-3.0M | 2015-10-01 – 2016-09-30 | evidence 0001607062-16-001092 |
| FY 2015 | $-2.0M | 2014-10-01 – 2015-09-30 | evidence 0001607062-16-001092 |
| FY 2014 | $-706.4k | 2013-10-01 – 2014-09-30 | evidence 0001607062-14-000203 |
| FY 2013 | $-842.9k | 2012-04-24 – 2014-03-31 | evidence 0001554795-14-000345 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).